ReviewNature reviews. Urology2026
SRD5A2 and emerging therapies in androgen-driven disorders.
Review in Nature reviews. Urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Intraprostatic steroid hormones and endocrine disruptors in prostate cancer.Endocrine-related cancer · 2026Article
- A Metabolic-Related Gene Signature for Predicting Biochemical Recurrence After Radical Prostatectomy: An Integrative Analysis and Targeted Therapeutic Validation.International journal of molecular sciences · 2026Article
- Fast Motions in 5 Alpha Reductase and Its Impact on Enzyme Kinetics.ACS catalysis · 2026Article
- Decoding benign prostatic hyperplasia at single-cell resolution: heterogeneity, inflammation, and beyond androgen-driven pathogenesis.Frontiers in immunology · 2026Review
- Integrative analysis reveals PRKCB and SRD5A2 as potential immune-associated biomarkers in prostate cancer targeted by traditional Chinese medicine.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Benign prostatic hyperplasia (BPH) is one of the most prevalent urological disorders in ageing men. Medical therapies are widely used to treat BPH, but truly effective long-term treatments remain limited. Among the most commonly prescribed drugs are 5α-reductase inhibitors (5ARIs), which alleviate symptoms and slow disease progression by inhibiting steroid 5α-reductase (SRD5A) enzymes, particularly the SRD5A1 and SRD5A2 isoforms. SRD5A2, the dominant isoform in the prostate, has a pivotal role in androgen metabolism by converting testosterone into dihydrotestosterone, a potent driver of prostate growth. Proper regulation of SRD5A2 is essential to maintain the balance between androgenic and oestrogenic signalling, thereby supporting healthy prostate physiology. Emerging evidence links SRD5A2 alterations, such as genetic polymorphisms, epigenetic silencing and inflammation-induced changes to disease risk and progression, positioning these factors as promising biomarkers for personalized therapy. Beyond BPH, SRD5A2 has also been implicated as a potential therapeutic target in prostate cancer and androgenic alopecia. Thus, SRD5A2 has clinical relevance in BPH, prostate cancer and other androgen-mediated conditions. However, limitations of SRD5A2-targeted therapies need to be overcome for future strategies to enhance the efficacy of 5ARI-based treatments.
Indexed as
Identifiers
41501168What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.